Search

everythinglearnresearchcommunity

for

Search:↓

A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

Hormone therapy for breast cancer often leads to sexual issues like vaginal dryness and decreased libido.

An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.

Understanding breast cancer requires considering both medical advancements and social influences.

Pranic meditation significantly improved mental health and quality of life for breast cancer survivors.

Some early breast cancer patients have long-term hair loss after chemotherapy, especially older and postmenopausal women.

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.

Docetaxel and paclitaxel for breast cancer can cause permanent, severe hair loss.

Hair from breast cancer patients shows changes in structure and composition, and a test using these changes detected cancer but also falsely identified some healthy samples as cancerous.

X-ray diffraction of hair might help detect breast cancer non-invasively.

Xiaoaiping reduces chemotherapy side effects and improves quality of life for breast cancer patients.

ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.

Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.

Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

Research from 2011 to 2020 shows androgen receptors could be key for prognosis and treatment in certain breast cancers.

Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.

The conclusion is that thorough investigation of hypertension and hormonal dysfunctions is important, and there may be a link between these conditions and cancer.

The paper concludes that breast cancer treatment involves complex interactions between medical symptoms, patient experiences, and commercial influences, requiring a holistic approach.

Radiation therapy in breast cancer patients changes gene expression related to DNA damage, fibroblast growth, and hair follicle development, which could help improve treatment for radiation-induced fibrosis.

Docetaxel treatment for breast cancer can cause permanent hair loss.

Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.

Scalp cooling is largely ineffective in preventing hair loss from breast cancer chemotherapy.

Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.

Patients with HR+/HER2- advanced breast cancer commonly experience fatigue, hair loss, and pain, which significantly affect daily activities.

Madarosis (eyebrow and eyelash loss) significantly affects quality of life for breast cancer patients on taxane-based chemotherapy.